Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 76282-524

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 76282-524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lurasidone Hydrochloride Tablets_120mg (Lurasidone HCl 120 mg)

Label for Lurasidone Hydrochloride Tablets 120 mg by Exelan Pharmaceuticals Inc. Displays medication name, strength, quantity (30 tablets), and storage instructions. Includes barcode, NDC number 76282-525-30, and manufacturing information for InvaGen Pharmaceuticals and Exelan Pharmaceuticals.*

FDA Label Image

Lurasidone Hydrochloride Tablets_20mg (Lurasidone HCl 20 mg)

Label for Lurasidone Hydrochloride Tablets 20 mg by Exelan Pharmaceuticals Inc. The label includes the NDC 76282-522-30, indicates a package count of 30 tablets, and features storage instructions. It notes pharmacist dispensing instructions and manufacturer details for InvaGen Pharmaceuticals and Exelan Pharmaceuticals.*

FDA Label Image

Lurasidone Hydrochloride Tablets_40mg (Lurasidone HCl 40 mg)

Label for Lurasidone Hydrochloride Tablets 40 mg, film-coated oral tablets. The label states the NDC 76282-523-30 and indicates a package of 30 tablets. It includes storage instructions, manufacturer information for InvaGen Pharmaceuticals, Inc., and is labeled for Exelan Pharmaceuticals, Inc. The label features a barcode, a note about usual dosage, and a pharmacist advisory to dispense the Medication Guide separately.*

FDA Label Image

Lurasidone Hydrochloride Tablets_60mg (Lurasidone HCl 60 mg)

Label for Lurasidone Hydrochloride 60 mg film-coated tablets, oral administration, manufactured for Exelan Pharmaceuticals Inc. The label includes the NDC 76282-534-30, a quantity of 30 tablets per bottle, pharmacist dispensing information, storage conditions, and manufacturer details (InvaGen Pharmaceuticals, Inc., Hauppauge, NY). Dimensions for label application (1.0" x 1.3") and a barcode are also present.*

FDA Label Image

Lurasidone Hydrochloride Tablets_80mg (Lurasidone HCl 80 mg)

Label for Lurasidone Hydrochloride 80 mg film-coated tablets, containing 30 tablets per package. The label includes the NDC number 76282-524-30 and states Rx Only. It notes dispensing the Medication Guide to patients and provides storage instructions. Manufactured for Exelan Pharmaceuticals Inc., Boca Raton, FL, and manufactured by InvaGen Pharmaceuticals, Inc., Hauppauge, NY.*

FDA Label Image

Lurasidone Hydrochloride_fig1 (Lurasidone Fig01)

A pharmacokinetic (PK) chart showing the fold change and 90% confidence interval of lurasidone levels when co-administered with various CYP3A4 inhibitors and inducers. It displays the impact on Cmax and AUC of strong inhibitors (ketoconazole 400 mg/day), moderate inhibitors (diltiazem 240 mg/day), and strong inducers (rifampin 600 mg/day and lithium 600 mg BID) relative to lurasidone alone.*

FDA Label Image

Lurasidone Hydrochloride_fig2 (Lurasidone Fig02)

A forest plot chart showing fold change and 90% confidence intervals for pharmacokinetic parameters of various interacting drugs compared to the drugs alone. The chart lists drugs including Digoxin 0.25 mg, Midazolam 5 mg, Ethinyl Estradiol, Norethindrone, and Lithium 600 mg BID, with corresponding pharmacokinetic measures such as Cmax, AUC, and trough levels plotted on a horizontal axis representing fold change from -1.0 to 1.0.*

FDA Label Image

Lurasidone Hydrochloride_fig3 (Lurasidone Fig03)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals in Cmax and AUC values for Lurasidone Hydrochloride. The chart compares these parameters across different degrees of renal and hepatic impairment (mild, moderate, severe) and population subgroups based on gender, race, and Asian ethnicity, showing changes relative to a reference group.*

FDA Label Image

Lurasidone_chemical Structure (Lurasidone Structure01)

Chemical structure of Lurasidone Hydrochloride, showing its molecular framework including multiple fused rings and a hydrochloride salt component, consistent with the active ingredient Lurasidone Hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.